---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-118535"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T19:16:00.398981+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eloxx Q3 net loss $7.5M ($0.09/share); Alport Phase 2 trial started, CF combo misses endpoints

## Summary
- Net loss of $7.5M vs $9.9M in prior-year quarter; R&D expense $4.9M, G&A $2.3M.
- Cash $24.6M as of Sep 30, 2022; expects funding into Q4 2023 subject to covenant compliance.
- Phase 2 Alport trial (NCT05448755) dosed first patient; topline results expected H1 2023.
- Phase 2 CF combination (ELX-02 + ivacaftor) did not meet efficacy endpoints; path forward to be determined with CF Foundation.
- ZKN-013 IND for RDEB on track for end of 2022 / early 2023; preclinical data presented for TURBO-ZM platform.

## SEC filing metadata
- accession: 0001104659-22-118535
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465922118535/0001104659-22-118535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465922118535/tm2230297d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-118535
- JSON: https://secwatch.observer/filing/0001104659-22-118535.json
- Plain text: https://secwatch.observer/filing/0001104659-22-118535.txt

## Key facts
- Earnings Releases
  Eloxx Pharmaceuticals, Inc. reported three months ended September 30, 2022 results: net income net loss of $7.5 million, or $0.09 per share, EPS $0.09 per share.
  - Period: three months ended September 30, 2022
  - Net income: net loss of $7.5 million, or $0.09 per share
  - EPS: $0.09 per share
  - Result: reported results
  source text: For the three months ended September 30, 2022, we incurred a net loss of $7.5 million, or $0.09 per share, which included $0.7 million in stock-based compensation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465922118535/0001104659-22-118535-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.